Kyverna Therapeutics, Inc. (KYTX) Cash Flow Statement
Kyverna Therapeutics, Inc. (KYTX) generated -$158.8M of operating cash flow over the twelve months to 2026-06-30, spent $1.5M on capital expenditure and had free cash flow of -$160.2M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KYTXKyverna Therapeutics, Inc.Follow KYTX — free
—
Price chart with a free account
- Market cap
- 333.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating cash flow | -114.3 | -153.7 | -158.8 | |
| Capital expenditure | 2.2 | 1.1 | -1.5 | |
| Free cash flow | -116.5 | -154.8 | -160.2 | |
| Stock-based compensation | 8.4 | 10.1 | — |
USD millions · SEC XBRL
Kyverna Therapeutics, Inc. — questions
- What is Kyverna Therapeutics, Inc.'s operating cash flow?
- -$158.8M over the twelve months to 2026-06-30.
- How much does Kyverna Therapeutics, Inc. spend on capital expenditure?
- $1.5M over the twelve months to 2026-06-30.
- What is Kyverna Therapeutics, Inc.'s free cash flow?
- -$160.2M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Kyverna Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.